Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR4 | P22455 | 16/20 | 0.68 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.66 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.66 |
| ▸ | FGFR3 | P22607 | 4/20 | 0.66 |
| ▸ | JAK3 | P52333 | 1/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.53 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.48 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17857066 | 0.89 | FGFR4 (0.82) | FGFR4FGFR1FGFR2FGFR3JAK3 | |
| SCHEMBL21166454 | 0.85 | FGFR4 (0.81) | FGFR4FGFR1FGFR2FGFR3JAK3 | |
| SCHEMBL16137352 | 0.83 | FGFR4 (0.78) | FGFR4FGFR1FGFR2FGFR3JAK3 | |
| SCHEMBL22532594 | 0.82 | FGFR4 (0.71) | FGFR4FGFR1FGFR2FGFR3JAK3 | |
| SCHEMBL24490094 | 0.82 | FGFR4 (0.71) | FGFR4FGFR1FGFR2FGFR3JAK3 | |
| SCHEMBL22532360 | 0.82 | FGFR4 (0.71) | FGFR4FGFR1FGFR2FGFR3JAK3 | |
| SCHEMBL19441991 | 0.82 | FGFR4 (0.84) | FGFR4FGFR1FGFR2FGFR3JAK3 | |
| SCHEMBL3971306 | 0.81 | FGFR4 (0.53) | FGFR4FGFR1FGFR2FGFR3 | |
| SCHEMBL22532311 | 0.81 | FGFR4 (0.70) | FGFR4FGFR1FGFR2FGFR3JAK3 | |
| SCHEMBL16134036 | 0.81 | FGFR4 (1.00) | FGFR4FGFR1FGFR2FGFR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783504-B2 | Kinase inhibitors for the treatment of disease | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-9783504-B2 | Kinase inhibitors for the treatment of disease | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160176825-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
| US-20160176825-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176825-A1 | KINASE INHIBITORS FOR THE TREATMENT OF DISEASE | BLK, ROS1, TEC | FGFR4 40/4885FGFR1 27/4885FGFR2 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.